Header Logo

Connection

NICOLA HANANIA to Female

Back to Details
This is a "connection" page, showing publications NICOLA HANANIA has written about Female.
NICOLA HANANIA
Connection Strength
1.219
Female
  1. Sex differences and determinants of anxiety symptoms in patients with COPD initiating pulmonary rehabilitation. Respir Med. 2024 06; 227:107633.
    View in: PubMed
    Score: 0.036
  2. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA. Int J Chron Obstruct Pulmon Dis. 2023; 18:407-418.
    View in: PubMed
    Score: 0.034
  3. The effectiveness of pulmonary rehabilitation on chronic obstructive pulmonary disease patients with concurrent presence of comorbid depression and anxiety. Respir Med. 2022 06; 197:106850.
    View in: PubMed
    Score: 0.031
  4. Predictors of premature discontinuation and prevalence of dropouts from a pulmonary rehabilitation program in patients with chronic obstructive pulmonary disease. Respir Med. 2022 03; 193:106742.
    View in: PubMed
    Score: 0.031
  5. Association of Triglyceride-Glucose Index and Lung Health: A Population-Based Study. Chest. 2021 09; 160(3):1026-1034.
    View in: PubMed
    Score: 0.029
  6. Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies. Int J Chron Obstruct Pulmon Dis. 2021; 16:865-875.
    View in: PubMed
    Score: 0.029
  7. Long-Term Benefits of Pulmonary Rehabilitation in Patients With COPD: A 2-Year Follow-Up Study. Chest. 2021 03; 159(3):967-974.
    View in: PubMed
    Score: 0.028
  8. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial. Chest. 2021 03; 159(3):985-995.
    View in: PubMed
    Score: 0.028
  9. Validity and Responsiveness of the?Depression Anxiety Stress Scales-21?(DASS-21) in?COPD. Chest. 2019 06; 155(6):1166-1177.
    View in: PubMed
    Score: 0.025
  10. Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:117-127.
    View in: PubMed
    Score: 0.025
  11. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019 04; 143(4):1629-1633.e2.
    View in: PubMed
    Score: 0.025
  12. Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts. J Am Med Dir Assoc. 2017 Dec 01; 18(12):1063-1068.
    View in: PubMed
    Score: 0.023
  13. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018 02; 73(2):490-497.
    View in: PubMed
    Score: 0.023
  14. Factors associated with depressive symptoms in uncontrolled asthmatics. J Asthma. 2018 05; 55(5):555-560.
    View in: PubMed
    Score: 0.023
  15. Effect of Yoga Breathing (Pranayama) on Exercise Tolerance in Patients with Chronic Obstructive Pulmonary Disease: A Randomized, Controlled Trial. J Altern Complement Med. 2017 Sep; 23(9):696-704.
    View in: PubMed
    Score: 0.023
  16. Assessing Patient and Provider Perceptions of Factors Associated with Patient Engagement in Asthma Care. Ann Am Thorac Soc. 2017 May; 14(5):659-666.
    View in: PubMed
    Score: 0.022
  17. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension? Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017 05; 126:105-115.
    View in: PubMed
    Score: 0.022
  18. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016 10; 4(10):781-796.
    View in: PubMed
    Score: 0.021
  19. The Responsiveness of the Anxiety Inventory for Respiratory Disease Scale Following Pulmonary Rehabilitation. Chest. 2016 07; 150(1):188-95.
    View in: PubMed
    Score: 0.021
  20. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015 Aug; 70(8):748-56.
    View in: PubMed
    Score: 0.019
  21. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. Respir Med. 2014 Feb; 108(2):366-75.
    View in: PubMed
    Score: 0.017
  22. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013 Apr 15; 187(8):804-11.
    View in: PubMed
    Score: 0.017
  23. Effect of a primary care continuing education program on clinical practice of chronic obstructive pulmonary disease: translating theory into practice. Mayo Clin Proc. 2012 Sep; 87(9):862-70.
    View in: PubMed
    Score: 0.016
  24. The efficacy and safety of the novel long-acting ?2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012 Jul; 142(1):119-127.
    View in: PubMed
    Score: 0.016
  25. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012 Jan; 106(1):91-101.
    View in: PubMed
    Score: 0.015
  26. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. Respir Med. 2011 Oct; 105(10):1516-22.
    View in: PubMed
    Score: 0.015
  27. Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population. COPD. 2011 Aug; 8(4):293-9.
    View in: PubMed
    Score: 0.015
  28. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011 05 03; 154(9):573-82.
    View in: PubMed
    Score: 0.015
  29. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res. 2011 Jan 11; 12:6.
    View in: PubMed
    Score: 0.014
  30. Response to salbutamol in patients with mild asthma treated with nadolol. Eur Respir J. 2010 Oct; 36(4):963-5.
    View in: PubMed
    Score: 0.014
  31. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med. 2011 Mar 01; 183(5):604-11.
    View in: PubMed
    Score: 0.014
  32. Burden of COPD in a government health care system: a retrospective observational study using data from the US Veterans Affairs population. Int J Chron Obstruct Pulmon Dis. 2010 May 06; 5:125-32.
    View in: PubMed
    Score: 0.014
  33. Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ). Respir Med. 2010 Aug; 104(8):1160-70.
    View in: PubMed
    Score: 0.014
  34. The safety and efficacy of arformoterol and formoterol in COPD. COPD. 2010 Feb; 7(1):17-31.
    View in: PubMed
    Score: 0.013
  35. Asthma in the elderly: current knowledge and future directions. Curr Opin Pulm Med. 2010 Jan; 16(1):55-9.
    View in: PubMed
    Score: 0.013
  36. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs. 2009 Jun 18; 69(9):1205-16.
    View in: PubMed
    Score: 0.013
  37. Evaluation of obstructive lung disease with vibration response imaging. J Asthma. 2008 Dec; 45(10):923-30.
    View in: PubMed
    Score: 0.012
  38. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther. 2008; 21(1):134-41.
    View in: PubMed
    Score: 0.011
  39. The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma. Respir Med. 2007 May; 101(5):1007-14.
    View in: PubMed
    Score: 0.011
  40. Acute asthma in pregnancy. Crit Care Med. 2005 Oct; 33(10 Suppl):S319-24.
    View in: PubMed
    Score: 0.010
  41. Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2025 Mar; 13(3):234-243.
    View in: PubMed
    Score: 0.010
  42. The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD. Pulm Pharmacol Ther. 2005; 18(1):19-22.
    View in: PubMed
    Score: 0.009
  43. Association of Insulin Resistance With Radiographic Lung Abnormalities and Incident Lung Disease: The Framingham Offspring Study. Diabetes Care. 2025 Jan 01; 48(1):143-148.
    View in: PubMed
    Score: 0.009
  44. Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS). Respir Med. 2025 Jan; 236:107846.
    View in: PubMed
    Score: 0.009
  45. Acute asthma in pregnancy. Crit Care Clin. 2004 Oct; 20(4):731-45, x.
    View in: PubMed
    Score: 0.009
  46. Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2372-2380.e5.
    View in: PubMed
    Score: 0.009
  47. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med. 2024 06 27; 390(24):2274-2283.
    View in: PubMed
    Score: 0.009
  48. Identification of sleep phenotypes in COPD using machine learning-based cluster analysis. Respir Med. 2024 06; 227:107641.
    View in: PubMed
    Score: 0.009
  49. Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. J Allergy Clin Immunol. 2004 Apr; 113(4):717-24.
    View in: PubMed
    Score: 0.009
  50. Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. J Allergy Clin Immunol Pract. 2024 May; 12(5):1215-1224.e3.
    View in: PubMed
    Score: 0.009
  51. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003 Sep; 124(3):834-43.
    View in: PubMed
    Score: 0.009
  52. Prevalence of abnormal spirometry in individuals with a smoking history and no known obstructive lung disease. Respir Med. 2023 03; 208:107126.
    View in: PubMed
    Score: 0.008
  53. Severe Monkeypox in Hospitalized Patients - United States, August 10-October 10, 2022. MMWR Morb Mortal Wkly Rep. 2022 Nov 04; 71(44):1412-1417.
    View in: PubMed
    Score: 0.008
  54. Clinical Markers Associated With Risk of Suicide or Drug Overdose Among Individuals With?Smoking Exposure: A Longitudinal Follow-up Study of the COPDGene Cohort. Chest. 2023 02; 163(2):292-302.
    View in: PubMed
    Score: 0.008
  55. Association of Systemic Inflammation with Depressive Symptoms in Individuals with COPD. Int J Chron Obstruct Pulmon Dis. 2021; 16:2515-2522.
    View in: PubMed
    Score: 0.008
  56. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021 01; 9(1):69-84.
    View in: PubMed
    Score: 0.007
  57. Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment. Thorax. 2020 09; 75(9):735-743.
    View in: PubMed
    Score: 0.007
  58. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2020 11; 125(5):565-576.e1.
    View in: PubMed
    Score: 0.007
  59. Prospective, Single-Arm, Longitudinal Study of Biomarkers in Real-World Patients with Severe Asthma. J Allergy Clin Immunol Pract. 2020 09; 8(8):2630-2639.e6.
    View in: PubMed
    Score: 0.007
  60. The Hospital Readmissions Reduction Program and Readmissions for Chronic Obstructive Pulmonary Disease, 2006-2015. Ann Am Thorac Soc. 2020 04; 17(4):450-456.
    View in: PubMed
    Score: 0.007
  61. Design of a home-based intervention for Houston-area African-American adults with asthma: Methods and lessons learned from a pragmatic randomized trial. Contemp Clin Trials. 2020 04; 91:105977.
    View in: PubMed
    Score: 0.007
  62. Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. Respir Med. 2019 Jul - Aug; 154:86-92.
    View in: PubMed
    Score: 0.006
  63. Clinical Epidemiology of COPD: Insights From 10 Years of the COPDGene Study. Chest. 2019 08; 156(2):228-238.
    View in: PubMed
    Score: 0.006
  64. Symptoms of anxiety and depression and use of anxiolytic-hypnotics and antidepressants in current and former smokers with and without COPD - A cross sectional analysis of the COPDGene cohort. J Psychosom Res. 2019 03; 118:18-26.
    View in: PubMed
    Score: 0.006
  65. Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2). Pulm Pharmacol Ther. 2018 Dec; 53:20-26.
    View in: PubMed
    Score: 0.006
  66. Effect of exposure to low levels of ozone on the response to inhaled allergen in allergic asthmatic patients. Chest. 1998 Sep; 114(3):752-6.
    View in: PubMed
    Score: 0.006
  67. Results of a Pulmonologist Survey Regarding Knowledge and Practices With Inhalation Devices for COPD. Respir Care. 2018 07; 63(7):840-848.
    View in: PubMed
    Score: 0.006
  68. Results of a Patient Survey Regarding COPD Knowledge, Treatment Experiences, and Practices With Inhalation Devices. Respir Care. 2018 07; 63(7):833-839.
    View in: PubMed
    Score: 0.006
  69. Step-Down Therapy for Asthma Well Controlled on Inhaled Corticosteroid and Long-Acting Beta-Agonist: A Randomized Clinical Trial. J Allergy Clin Immunol Pract. 2018 Mar - Apr; 6(2):633-643.e1.
    View in: PubMed
    Score: 0.006
  70. Obesity modulates diaphragm curvature in subjects with and without COPD. Am J Physiol Regul Integr Comp Physiol. 2017 Nov 01; 313(5):R620-R629.
    View in: PubMed
    Score: 0.006
  71. Trends in 30-day readmission rates after COPD hospitalization, 2006-2012. Respir Med. 2017 Sep; 130:92-97.
    View in: PubMed
    Score: 0.006
  72. The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort. J Am Med Dir Assoc. 2017 Nov 01; 18(11):955-959.e6.
    View in: PubMed
    Score: 0.006
  73. Factors associated with emergency department dependence of patients with asthma. Chest. 1997 Feb; 111(2):290-5.
    View in: PubMed
    Score: 0.005
  74. Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017 02 01; 195(3):324-330.
    View in: PubMed
    Score: 0.005
  75. Fungal Sensitization Is Associated with Increased Risk of Life-Threatening Asthma. J Allergy Clin Immunol Pract. 2017 Jul - Aug; 5(4):1025-1031.e2.
    View in: PubMed
    Score: 0.005
  76. Obesity Is Associated With Increased Morbidity in Moderate to Severe COPD. Chest. 2017 Jan; 151(1):68-77.
    View in: PubMed
    Score: 0.005
  77. Characteristics and outcomes of older adults with long-standing versus late-onset asthma. J Asthma. 2017 04; 54(3):223-229.
    View in: PubMed
    Score: 0.005
  78. Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2016 07; 13(7):1016-25.
    View in: PubMed
    Score: 0.005
  79. Assessing biomarkers in a real-world severe asthma study (ARIETTA). Respir Med. 2016 06; 115:7-12.
    View in: PubMed
    Score: 0.005
  80. Long-term Course of Depression Trajectories in Patients With COPD: A 3-Year Follow-up Analysis of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Cohort. Chest. 2016 Apr; 149(4):916-26.
    View in: PubMed
    Score: 0.005
  81. Age-Related Differences in Health-Related Quality of Life in COPD: An Analysis of the COPDGene and SPIROMICS Cohorts. Chest. 2016 Apr; 149(4):927-35.
    View in: PubMed
    Score: 0.005
  82. Differences between absolute and predicted values of forced expiratory volumes to classify ventilatory impairment in chronic obstructive pulmonary disease. Respir Med. 2016 Feb; 111:30-8.
    View in: PubMed
    Score: 0.005
  83. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol. 1995 Nov; 96(5 Pt 1):571-9.
    View in: PubMed
    Score: 0.005
  84. Health-care utilization after near-fatal asthma. Chest. 1995 Jun; 107(6):1564-9.
    View in: PubMed
    Score: 0.005
  85. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015 Jan; 12(1):27-34.
    View in: PubMed
    Score: 0.005
  86. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014 Dec; 146(6):1531-1542.
    View in: PubMed
    Score: 0.005
  87. A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation. Respir Med. 2014 Sep; 108(9):1310-20.
    View in: PubMed
    Score: 0.005
  88. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma. J Biol Chem. 2014 May 02; 289(18):12623-32.
    View in: PubMed
    Score: 0.004
  89. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol. 2013 Dec; 132(6):1295-302.
    View in: PubMed
    Score: 0.004
  90. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013 May; 1(3):210-23.
    View in: PubMed
    Score: 0.004
  91. Perceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectives. COPD. 2013 Aug; 10(4):482-92.
    View in: PubMed
    Score: 0.004
  92. Comparative effectiveness of noninvasive ventilation vs invasive mechanical ventilation in chronic obstructive pulmonary disease patients with acute respiratory failure. J Hosp Med. 2013 Apr; 8(4):165-72.
    View in: PubMed
    Score: 0.004
  93. Age-related differences in asthma outcomes in the United States, 1988-2006. Ann Allergy Asthma Immunol. 2013 Apr; 110(4):240-6, 246.e1.
    View in: PubMed
    Score: 0.004
  94. Racial differences in CT phenotypes in COPD. COPD. 2013 Feb; 10(1):20-7.
    View in: PubMed
    Score: 0.004
  95. Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. Health Qual Life Outcomes. 2012 Aug 23; 10:100.
    View in: PubMed
    Score: 0.004
  96. A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. COPD. 2012 Apr; 9(2):151-9.
    View in: PubMed
    Score: 0.004
  97. Age-related differences in clinical outcomes for acute asthma in the United States, 2006-2008. J Allergy Clin Immunol. 2012 May; 129(5):1252-1258.e1.
    View in: PubMed
    Score: 0.004
  98. Glucose and pyruvate metabolism in severe chronic obstructive pulmonary disease. J Appl Physiol (1985). 2012 Jan; 112(1):42-7.
    View in: PubMed
    Score: 0.004
  99. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011 Sep 22; 365(12):1088-98.
    View in: PubMed
    Score: 0.004
  100. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology. 2011 Oct; 261(1):274-82.
    View in: PubMed
    Score: 0.004
  101. Gender differences of airway dimensions in anatomically matched sites on CT in smokers. COPD. 2011 Aug; 8(4):285-92.
    View in: PubMed
    Score: 0.004
  102. Racial differences in quality of life in patients with COPD. Chest. 2011 Nov; 140(5):1169-1176.
    View in: PubMed
    Score: 0.004
  103. Measuring the impact of a live, case-based, multiformat, interactive continuing medical education program on improving clinician knowledge and competency in evidence-based COPD care. Int J Chron Obstruct Pulmon Dis. 2011; 6:297-307.
    View in: PubMed
    Score: 0.004
  104. Resting energy expenditure and protein turnover are increased in patients with severe chronic obstructive pulmonary disease. Metabolism. 2011 Oct; 60(10):1449-55.
    View in: PubMed
    Score: 0.004
  105. Prevalence of airway obstruction assessed by lung function questionnaire. Mayo Clin Proc. 2011 May; 86(5):375-81.
    View in: PubMed
    Score: 0.004
  106. Development of the Lung Function Questionnaire (LFQ) to identify airflow obstruction. Int J Chron Obstruct Pulmon Dis. 2010 Feb 18; 5:1-10.
    View in: PubMed
    Score: 0.003
  107. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease. Adv Ther. 2009 Nov; 26(11):1024-34.
    View in: PubMed
    Score: 0.003
  108. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. Ther Adv Respir Dis. 2008 Aug; 2(4):199-208.
    View in: PubMed
    Score: 0.003
  109. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Ther Adv Respir Dis. 2008 Apr; 2(2):37-48.
    View in: PubMed
    Score: 0.003
  110. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD. 2008 Feb; 5(1):25-34.
    View in: PubMed
    Score: 0.003
  111. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. Clin Ther. 2008; 30 Spec No:989-1002.
    View in: PubMed
    Score: 0.003
  112. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007 Feb; 29(2):261-78.
    View in: PubMed
    Score: 0.003
  113. Predicting episodes of poor asthma control in treated patients with asthma. J Allergy Clin Immunol. 2006 Dec; 118(6):1226-33.
    View in: PubMed
    Score: 0.003
  114. A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med. 2006 May; 24(3):259-67.
    View in: PubMed
    Score: 0.003
  115. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther. 2005 May; 27(5):531-42.
    View in: PubMed
    Score: 0.002
  116. The accuracy of a handheld portable spirometer. Chest. 1996 Jan; 109(1):152-7.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.